SGLT2 Inhibitors and Risk for Ketoacidosis and Urinary Tract Infections

Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.

Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.

This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.